ChemicalBook > Product Catalog >Biochemical Engineering >Biochemical Reagents >Agonist Inhibitors >TG6-10-1

TG6-10-1

TG6-10-1 Suppliers list
Company Name: Shanghai Boyle Chemical Co., Ltd.  
Tel:
Email: sales@boylechem.com
Company Name: Carbott PharmTech Inc.  
Tel: 0535-6385396
Email: info@carbottpharm.com
Company Name: Haoyuan Chemexpress Co., Ltd.  
Tel: 021-58950125
Email: info@chemexpress.com
Company Name: MedChemexpress LLC  
Tel: 021-58955995
Email: sales@medchemexpress.cn
Company Name: Shanghai JiYi Biotechnology Co. Ltd.  
Tel: 13621943973
Email: sales@shjiyipharmatech.com

TG6-10-1 manufacturers

  • TG6-10-1
  • 	TG6-10-1 pictures
  • $1.00
  • 2019-09-06
  • CAS:1415716-58-3
  • Min. Order: 1ASSAYS
  • Purity: 95%~99%
TG6-10-1 Basic information
Product Name:TG6-10-1
Synonyms:TG6-10-1;(E)-N-(2-(2-(trifluoromethyl)-1H-indol-3-yl)ethyl) -3-(3,4,5-trimethoxyphenyl)acrylamide;CS-2074;TG6-10-1, >98%;2-Propenamide, N-[2-[2-(trifluoromethyl)-1H-indol-1-yl]ethyl]-3-(3,4,5-trimethoxyphenyl)-, (2E)-;TG6-10-1, 10 mM in DMSO;Prostaglandin EP2 Receptor Antagonist, TG6-10-1
CAS:1415716-58-3
MF:C23H23F3N2O4
MW:448.44
EINECS:
Product Categories:api;Inhibitors
Mol File:1415716-58-3.mol
TG6-10-1 Structure
TG6-10-1 Chemical Properties
Boiling point 631.8±55.0 °C(Predicted)
density 1.24±0.1 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMF: 50 mg/ml; DMSO: 30 mg/ml; Ethanol: 5 mg/ml
form A crystalline solid
pka13.84±0.46(Predicted)
color White to off-white
InChI1S/C23H23F3N2O4/c1-30-18-12-15(13-19(31-2)22(18)32-3)8-9-21(29)27-10-11-28-17-7-5-4-6-16(17)14-20(28)23(24,25)26/h4-9,12-14H,10-11H2,1-3H3,(H,27,29)
InChIKeyWUYOECAJFJFUFC-UHFFFAOYSA-N
SMILESCOC1=CC(=CC(=C1OC)OC)C=CC(=O)NCCN2C3=CC=CC=C3C=C2C(F)(F)F
Safety Information
WGK Germany WGK 3
Storage Class11 - Combustible Solids
MSDS Information
TG6-10-1 Usage And Synthesis
UsesTG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors[1].
Biological ActivityPrimary Target
EP2', 'Reversible: yes
Synthesis
3,4,5-TRIMETHOXYCINNAMIC ACID

20329-98-0

1H-Indole-1-ethanamine, 2-(trifluoromethyl)-

1415601-84-1

TG6-10-1

1415716-58-3

General procedure for the synthesis of (E)-N-(2-(2-(2-(trifluoromethyl)-1H-indol-1-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (15d): Compound 13b (480 mg, 2.1 mmol) was dissolved in dichloromethane (10 mL) at room temperature, and sequentially added (E)-3-(3,4,5-trimethoxyphenyl ) acrylic acid (14a) (504 mg, 2.1 mmol), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) (523 mg, 2.73 mmol) and N,N-dimethylaminopyridine (DMAP) (10 mg). The reaction mixture was stirred at room temperature for 8 hours. Upon completion of the reaction, the reaction was quenched with water (10 mL) and the product was extracted with ethyl acetate (20 mL × 3). The organic phases were combined and washed sequentially with 1% HCl (10 mL), saturated NaHCO3 solution (10 mL), water (20 mL), and brine (20 mL), then dried with anhydrous Na2SO4. After concentration under reduced pressure, the crude product was purified by silica gel column chromatography with the eluent being a hexane solution of 0-35% ethyl acetate to give the target product 15d (700 mg, 74% yield). The 1H NMR (CDCl3) data of product 15d: δ 7.59 (d, J = 8 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 15.2 Hz, 1H), 7.27 (q, J = 7.2 Hz, 1H), 7.1 (t, J = 7.2 Hz, 1H), 6.89 (s, 1H), 6.63 (s, 2H), 6.4 (t, J = 6 Hz, 1H), 6.25 (d, J = 15.2 Hz, 1H), 4.4 (t, J = 6.4 Hz, 1H), 3.8 (s, 3H), 3.76 (s, 6H), 3.69 (q, J = 6.4 Hz, 2H). lCMS (ESI) analysis: λ254 nm, MS purity > 95%; m /z 449 [M + H]+. Calculated elemental analysis (C23H23F3N2O4): C, 61.60; H, 5.17; N, 6.25; measured values: C, 61.34; H, 5.10; N, 6.16.

in vivo

TG6-10-1 (5 mg/kg; i.p.; 4-30 hours) improves survival, accelerates recovery of lost weight, and improves functional recovery following status epilepticus (SE) [1].

Animal Model:C57BL/6 mice (pilocarpine-induced SE)[1]
Dosage:5 mg/kg
Administration:Intraperitoneal injection; 4, 21, 30 hours
Result:A significant increase in survival and accelerating the recovery of lost weight in post-SE mice.
References[1] Jiang J, et al. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3591-3596. DOI:10.1073/pnas.1218498110
[2] Kang X, et al. Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Sci Rep. 2017 Aug 25;7(1):9459. DOI:10.1038/s41598-017-09528-z
Tag:TG6-10-1(1415716-58-3) Related Product Information
Fedratinib N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide 3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol N-(tert-Butyl)-3-[[5-methyl-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide 5-Pyridin-4-yl-1H-indazole TG4-155